Page 5 - Johnson Amp News Today

Shares of Johnson & Johnson (NYSE:JNJ – Get Free Report) have received a consensus recommendation of “Hold” from the twelve analysts that are presently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price […]

FDA clears Moderna's and Pfizer's Covid vaccine booster shots for all U.S. adults : Rashtra News Liesl Eibschutz, a medical student from Dartmouth University, loads a syringe with Pfizer COVID-19 vaccine before giving it to people on the first day that people ages 16 and up can receive the vaccine at Kedren Health on Thursday,

Jim Cramer reflects on Nvidia's GTC conference and identifies the companies that stand to gain the most through partnerships with the AI chip giant.

OPSYNVI® combines two proven treatments with established efficacy and safety profiles into one tablet to be taken once daily, offering an option that helps to...

West Paces Advisors Inc. lowered its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 4.6% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 3,642 shares of the company’s stock after selling 177 shares during the period. West Paces Advisors Inc.’s holdings in Johnson […]

PFS Partners LLC lowered its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 7.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,225 shares of the company’s stock after selling 97 shares during the quarter. PFS Partners LLC’s holdings in Johnson […]

B. Riley Wealth Advisors Inc. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 148,486 shares of the company’s stock after selling 817 shares during the quarter. Johnson & Johnson […]

/PRNewswire/ -- Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...

The submission could grant guselkumab its third indication, after being approved by the FDA for psoriasis and psoriatic arthritis.

A $10 million investment is aiming to reduce drug-related overdose deaths and overdose racial disparities in Michigan.